

Subject Index

- A** 2058 cells, TIMP-2 and, 234
- Activation
- MMP-1, 362
 - MMP-2 in human breast cancer and, 456
 - molecular weight changes accompanying, 436
 - oxidative, 127, 129
 - stromelysin-2, 367
 - tissue kallikrein and, 466
- Activators, regulation of MMP activity and, 31
- Active site, role of, in complex formation, 87
- Adhesion, melanoma cell, 233
- Adjuvant arthritis, 411
- connective tissue degradation and, 183
 - MMP-9 and, 484
- Aggrecan degradation, collagenases and, 182
- Aggrecanase activity, 380
- Alkali burn, rabbit cornea and, 209
- Alkaline proteinase, corneal damage and, 208
- 4-Aminophenylmercuric acetate (APMA), activation with, 297
- Angiogenesis
- cancer therapy and, 275
 - inhibition of
 - by anthracyclines and titanocene dichloride, 280
 - by GM 6001, 320
 - by tetracyclines, 266
 - TIMPs direct inhibitory effects on, 243
 - tumor, inhibition of, 263
- Angiogenesis model, screening with, 278
- Angiostatic steroids, antitumor potential of, 265
- Animal models, major human rheumatic diseases and, 183
- Animals, living, matrixins role in, 13
- Anthracyclines, effect of, on angiogenesis, 283
- Antiarthritic activity, preclinical, of MMP inhibitors, 411
- Antibiotic therapy, periodontitis and, 132
- Antibodies, blocking, 89
- Antimetastatic drugs, monitoring cancer treatment with, 258
- Antirheumatic drugs, 400
- Antisense TIMP-1 RNA, tumors and, 67
- α_1 -Antitrypsin, neutrophil elastase activity and, 303
- AP-1, MMP gene expression and, 45
- Arthritis
- collagen-induced, 184
 - stromelysin in, 348
- Articular cartilage, hypertrophic repair of, in osteoarthritis, 200
- Atherosclerosis, 462
- B** 16-F10 melanoma cells, metastatic, GM 6001 and, 321
- Balloon injury, 385
- Basic fibroblast growth factor, 462
- Batimastat (BB-94), 218
- Binding of gelatinases, 365
- Biphosphonates, 274
- Bone, turnover of, urinary pyridinoline and, 416
- Bone collagen ECM, resorption of, 166
- Bone loss, 96
- Bovine nasal cartilage, GAG and collagen fragments and, 78
- Breast cancer, human, 456
- C**^{Ca²⁺ sensor or receptor, osteoclast, 177}
- Calcitonin, loss of bone density and, 185
- Calvarial population, rat, 52
- Cancer
- MMP production in, 249
 - survival in, 275
- Cartilage, release of GAG fragments from, 75
- Cartilage biophysical properties, effects of MMPs on, 439
- Cartilage degradation, doxycycline inhibition of, 414
- Cartilage explants, IL-1-stimulated collagen degradation in, 395
- Cartilage plugs, 439
- Cartilage-derived factor, angiogenesis and, 264
- Catabolism, aggrecan, 380
- Catalytic domain, matrixins and, 15
- Catalytic latency, fibroblast-type collagenase and, 84
- Cathepsin L activity, secreted osteoclast, 176
- Cathepsins, bone resorption and, 168
- Cefotetan, uterine MMPs and, 495
- Cell migration, TIMP-1 and, 70
- Cell surface, association of MMPs with, 31
- Chemically modified tetracyclines, antimicrobial activity and, 97, 144, 165, 185
- Chloramphenicol acetyl transferase (CAT), retinoic acid and, 336
- Chondrocyte cultures, aggrecan catabolism in, 380
- Chondrocytes
- cell culture models comprising, 3
 - collagenase production by, 447

- Chondroprotection, 275
- Chorioallantoic membrane (CAM), chick, angiogenesis and, 282
- Circular dichroism spectroscopy, triple helical collagens and, 24
- Clinical studies, GM 6001 and, 322
- Clinical trial design, evaluation of MMP inhibitors and, 273
- Collagen
- bone matrix and, 166
 - gingival extracts and, 98
 - modulators of, 264
 - type I
 - binding of gelatinases A and B to, 365
 - collagenase cleavage of, 6
 - type IV, enzyme activity and, 276
- Collagen fragments, release of, from pig articular cartilage, 77
- Collagen-like domain, 372
- Collagenase
- active, gingival crevicular fluid and, 156
 - fibroblast-type, 84
 - first description of, 1
 - gastric carcinomas and, 217
 - human fibroblast, 22
 - human neutrophil, 22
 - interstitial, 294
 - neutrophil, gingival and salivary, 112
 - oral microorganisms and, 96
 - osteoarthritis and, 395
 - osteoclast lineage and, 472
 - porcine fibroblast, 208
 - role of, in bone resorption, 166
 - type IV
 - 92-kDa, 372
 - inhibition of angiogenesis and, 280
 - mouse 92-kDa, 369
- Collagenase gene expression, retinoic acid suppression of, 344
- Collagenase inhibition, *Porphyromonas gingivalis* and, 108
- Collagenase inhibitor complex, 377
- Complex formation, fibroblast-type collagenase and, 85
- Concanavalin A, regulation of MMP and TIMP by, 56
- Confocal laser scanning cytometry, human synovial fibroblasts and, 348
- Connective tissue, synthesis and degradation of, 51
- Controlled-release polymers, 265
- Corneal ulceration
- GM 6001 and, 318
 - peptide-based MMP inhibitors in, 206
- Cruciate-deficient dog, osteoarthritis and, 199
- Crystal structure of collagenase catalytic domain, 375
- β -Cysteinyl- γ -glutamyl thiolester, 294
- Cycloheximide, effects of, on MMP and TIMP, 54
- Cyclosporin A, bone damage ameliorated by, 185
- D**ecidual cells, 479
- Dexamethasone, inhibition of MMP gene expression by, 47
- Diagnosis, periodontal diseases and, 152
- Doxycycline
- breakdown of articular cartilage inhibited by, 201
 - cartilage matrix degradation and, 414
 - effect of, on UMR 106-01 gelatinase activity, 173
 - in vivo* effect of, 431
 - inhibition of urinary pyridinoline by, 416, 419
 - keratinocytes and, 140
 - Porphyromonas gingivalis* and, 97
 - postmenopausal bone damage and, 493
 - α_1 -protease inhibitor and, 304
- Doxycycline inhibition, molecular actions associated with, 113
- Drug combination, FDA approval and, 277
- Drugs, cartilage breakdown and, 482
- E**lastase, corneal damage and, 208
- gingival extracts and, 98
- ELISA
- sandwich type, 255
 - stromelysin enzyme activity and, 356
- Endometrium
- human, 479
 - MMP expression in, 43
- Endothelial cells, angiogenic factors and, 263
- Enzyme synthesis, reduction of MP levels by controlling, 335
- Epithelial cells, periodontal ligament, 141
- Erythroid potentiating activity, TIMP-1 and, 68-69
- Estrogen, MMP gene expression and, 45
- Ethylene vinyl acetate copolymer, 136
- Extracellular matrix (ECM)
- bone collagen, 166
 - degradation of, 31
 - interaction between tumor cells and, 222
 - matrixins and, 17
 - α_1 -protease inhibitor bound to, 303
- F**etal long bone, bone resorption and, 175
- Fibroblasts, cell culture models comprising, 3
- Fibronectin, adhesion of cell lines to, 238

Fluorogenic peptide, diagnostic accuracy of, 158
Fluorogenic substrate, 351
Flurbiprofen
 radiographic bone destruction and, 183
 tetracyclines combined with, 277
Fos, 335
Fumagillin, angiogenesis and, 264

G
Gel mobility shift assays, retinoic acid receptor and, 340
Gelatin-binding domain, MMP-9, 372
Gelatinase
 72-kDa, 208
 binding of, 365
 gingival crevicular fluid, 156
 jaw cyst expansion and, 486
 oral microorganisms and, 96
 osteoclast and, 168
Gelatinase A
 human malignant gliomas and, 450
 keratinocytes and, 140
Gelatinase B
 second disulfide knot and, 403
 tissue kallikrein and, 466
Gelatinase activator, 72-kDa, 57
Gene, mouse 92-kDa type IV collagenase, 369
Gene expression, retinoic acid and, 335
Genetic manipulation, MMP-TIMP balance and, 226, 228
Gingival collagenase, effects of tetracyclines on, 112
Gingival crevicular fluid
 diagnostic potential of, 153
 HIV subjects and, 476
 measurements in, 278
 minocycline in, 133
 smokers and, 453
Gingival tissues, collagenase activity in, 96
Gliomas, human malignant, 450
Glycosaminoglycan (GAG) fragments, inhibition of, 75
Growth, tumor, angiogenesis and, 263
Growth rate, A2058 cell, TIMP-2 and, 243
Guinea pigs, spontaneous knee osteoarthritis in, 190

H
Hemopexin/vitronectin domain, matrixins and, 16
Hemopexin-like domain, 22
Heparin, antitumor potential of, 265
HIG82 cells, 337
Hinge region, fibroblast-type collagenase and, 84
HIV subjects, 476

Homologous recombination, Col1a1 gene and, 6
Homopolymers, anionic, 398
Human malignant gliomas, 450
Human neutrophil collagenase, periodontal diseases and, 155
Human tumor growth, 410

I
Implantation, repression of MMP expression and, 44
Inflammatory skin disease, phorbol ester model of, 319
Inhibition
 collagenase, Ca^{2+} and, 128
 direct, of oxidative activation, 129
 doxycycline, 125
Inhibitor binding, 489
Inhibitors, 31
 natural, 444
Insulin-like growth factor-1, treatment of canine osteoarthritis with, 392
Interleukin-1 β , stimulation of production of MPs by, 3
Interleukin-1 β -induced bone resorption, 379
Invasion, TIMP as inhibitor of, 70
Invasion and metastasis, tumor, role of MMPs in, 223
Invasive cascade, MMPs involved in, 244

J
Jaw cyst expansion, gelatinases/type IV collagenases in, 486
Jun, 335

K
Keratinocytes
 human gingival, 117
 human skin, MMP-2 gene expression in, 140
Keratitis, *Pseudomonas*, 208

L
Lymecycline, reactive arthritis and, 424
Lysosomal cysteine proteinases, bone resorption and, 168

M
 α_2 -Macroglobulin, interaction of MMPs with, 294
Mammalian expression system, 31
Matrigel, reconstituted basement membrane assay using, 326
Matrigel tube assay, 283
Matrilysin
 ConA induction of, 59
 metal ions in, 489
 rat, characterization of, 362
Matrix metalloproteinase (see MMP)
Matrixin family, enzyme belonging to, 11

- Melanoma cell adhesion and motility,
TIMP-2 and, 233
- Menstrual cycle, mRNA for 72-kDa
gelatinase A and, 44
- Metal ions, 489
- Metalloproteinase (*see* MP)
- Metastasis
cancer therapy and, 275
GM 6001 and, 321
- Metastatic capability, TIMP-1 and, 70
- Methotrexate, bone erosion and, 274
- Michaelis-Menten kinetics, 128
- Migration, 462
- Minocycline
angiogenesis and, 264
rheumatoid arthritis and, 422
rheumatoid collagenase inhibited by, 194
tumor angiogenesis inhibited by, 266
- Minocycline HCl, periodontal diseases and,
133
- MMP (matrix metalloproteinase) inhibition,
connective tissue breakdown and, 75
- MMP inhibitors, preclinical antiarthritic
activity of, 411
- MMP-1
matrilysin and, 362
role of, in bone resorption, 166
- MMP-1 synthesis, phorbol esters increasing,
335
- MMP-2
breast cancer and, 456
keratinocytes and, 140
- MMP-9
adjuvant arthritis and, 484
breast cancer cells and, 325
 α_2 -macroglobulin and, 294
monoclonal antibodies to, 469
one-step sandwich enzyme immunoassay
for, 359
substrate specificity and domain structure
of, 372
- MMPs
adult periodontitis and, 459
cancer cell tumorigenicity and, 222
cancer dissemination and, 249
cartilage biophysical properties and, 439
cellular sources of, 113
crystallographic binding code of peptide
inhibitor and, 400
degradation of ECM and, 324
family of, 11
fibroblast-type collagenase and, 84
gingival, 96
HIV subjects and, 476
human fibroblast collagenase and, 22
human neutrophil collagenase and, 22
low molecular weight, 217
lymecycline treatment on, 424
reactive arthritis and, 431
regulation of, 31
smokers and, 453
smooth muscle cells and, 384, 462
temporomandibular joint destruction and,
427
uterine, cefotetan and, 495
- Molecular weight changes, 436
- Monoclonal antibodies
anti-human MMP-9-specific, 325
MMP-9 and, 469
- Motility, melanoma cell, 233
- MP (metalloproteinase) activity
ovary and, 444
reduction in TIMP expression and, 68
- MP inhibitor, inhibition of tumor cell growth
in nude mice by, 408
- MP inhibitor complexes, identification of,
in human plasma, 253
- MPs
clinical importance of, 1
control of, 16
inhibition of angiogenesis and, 280
production of, controls of, 3
roles of, *in vivo*, 3
study of, genetic models for, 5
- Mutational analysis, TIMP-1 and, 88
- Mutations, site, 31
- N**eovascularization, dependence of solid
tumor growth upon, 263
- Neutrophil collagenase
effects of tetracyclines on, 112
 α_1 -protease inhibitor and, 303
- Neutrophil elastase, ECM degradation and,
303
- Neutrophil procollagenase, stromelysin-2
and, 367
- Non-antimicrobial chemically modified
tetracycline, 96, 148
bone resorption and, 165
- Nonsteroidal antiinflammatory drug
(NSAID), 427, 431
- Northern blot analysis, HIG82 cells and, 337
- Nutritional supplementation, 379
- O**rthovanadate, collagenase production
inhibited by, 447
- Osteoarthritis
canine, sodium pentosan polysulfate and,
392
clinical trials and, 274
collagen and proteoglycan degradation in,
182
collagen degradation in, 395
cruciate-deficient dog model of, 199

- Osteoblasts
cytoplasmic organelles in, 186
structure and function of, 167
- Osteoclasts
migration of, 167
rheumatoid arthritis and, 274
ruffled borders in, 186
- Osteotropic hormones, TIMP-1 and MMP
expression and, 52
- Outcome measure, 275
- Ovulation, gelatinases and endogenous
inhibitors and, 444
- P**arathyroid hormones, TIMP-1 and MMP
expression and, 52
- PEA-3, MMP gene expression and, 45
- Peptide substrates, enzyme assays and, 351
- Peptides, synthetic, transferrin degradation
inhibited by, 357
- Periarticular muscle, reduction in use of, 203
- Periodontal diseases
diagnostic tests of, 152
ECM degradation and, 122
MMPs and, 96
tetracyclines in treatment of, 96, 113, 133,
140
- Periodontal ligament, 141
- Periodontal pockets, diseased, 125
- Periodontitis
adult, MMP-1, -3, and -8 and, 459
Porphyromonas gingivalis-induced, 433
refractory, conventional treatment and,
278
tetracycline and, 177
- Peritonitis, thioglycollate-induced, 320
- Pexin-like repeats, fibroblast-type
collagenase and, 84
- Phorbol esters
MMP-1 synthesis increased by, 335
TIMP-1 gene modulation by, 56
- Pig articular cartilage, release of collagen
fragments from, 77
- Piroxicam, radiologic evidence of bone
destruction and, 184
- Plaque, dental, 127
- Plaque index, 134
- Plasma, MMP activity in, 249
- Plasmin, tissue kallikrein and, 466
- Plasminogen activator inhibitor-1, effect of
MMPs on degradation of, 311
- Platelet-derived growth factor, 462
- Podosomes, attachment of osteoclast
through, 170
- Porphyromonas gingivalis*, 96, 433
- Postmenopausal bone damage, doxycycline
inhibiting, 493
- Predicting metastasis, MMP-inhibitor
complexes in, 248
- Primate arterial smooth muscle cells, MMP-2
and MMP-9 and, 462
- Pro-M₉2K GL-TIMP-1 complex, 405
- Progelatinase A, TIMP-2 and, 389
- Progesterone, gelatinase A mRNA and, 44
- Progestins, decidualization and, 479
- ProMMP-9-TIMP-1 complexes, 297
- Propeptide domain, matrixins and, 14
- α_1 -Protease inhibitor, neutrophil elastase
activity and, 303
- Proteinase, *Porphyromonas gingivalis* and, 97
- Proteinase inhibitors, effects of, on aggrecan
catabolism, 380
- Proteoglycan epitope 3-B-3(-), 190
- Proteoglycan subunit, 398
- Proteolysis, monitoring, MMPs and, 243
- Pseudomonas aeruginosa*, 208
- Psoriasis, phorbol ester model of, 319
- Pyridinium cross-links, collagen-derived, 419
- Pyridinoline, 416, 419
- R**abbit immune-mediated synovitis, 184
- Rabbit synovial fibroblasts, 337
- Reactive arthritis
doxycycline in, 431
lymecycline treatment on serum MMPs in,
424
- Reactive oxygen species, activation of bone
procollagenase through, 169
- Recombinant human neutrophil
procollagenase, 436
- Remodeling, uncontrolled, 31
- Resorption, osteoblast as initiator of, 167
- Retinoic acid, regulation of MMP expression
and, 52
- 9-*cis* Retinoic acid, 336
- 13-*cis*-Retinoic acid, collagenase secretion
and, 184
- all-*trans* Retinoic acid, 336
- Retinoic acid receptors, 335
- Retinoids, gene expression and, 335
- Reverse transcriptase *in situ* polymerase
chain reaction, MMP-9 and, 325
- Rheumatoid arthritis
minocycline in, 422
MMPs role in, 1
treatment of, with MMP inhibitors, 182
urinary pyridinoline in, 416, 419
- S**alivary collagenase, effects of tetracyclines
on, 112
- Sandwich enzyme immunoassay, one-step,
for MMP-9, 359
- Sandwich type ELISA, 255
- SC 44463 and SC 40827, 362
- Screening test, periodontal diagnosis and,
157

- Second disulfide knot, 403
- Signal transduction/synthesis cascade,
transcription of MMP genes and, 4
- SIMP compound, collagenase and gelatinase
inhibited by, *in vitro*, 208
- Site-directed mutagenesis, murine Col1a1
gene and, 5
- Smokers, heavy, periodontal health and, 453
- Smooth muscle cells
MMPs expressed by, 384
primate arterial, 462
- Sodium pentosan polysulfate, treatment of
canine osteoarthritis with, 392
- Stromelysin
bovine articular cartilage and, 482
fluorogenic substrate for, 351
human synovial fibroblasts expressing, 348
plasma levels of, in cancer, 256
sequence identity and, 2
transferrin assay and, 356
- Stromelysin-1
decidualization and, 479
retinoic acid elevated, 53
- Stromelysin-2, neutrophil procollagenase
activated by, 367
- Subchondral bone, stiffening of, 203
- Synovial fluid, tissue events marked by, 274
- Synovitis, cartilage breakdown and, 201
- Synthetic inhibitors, 362
- T**emporomandibular joint, 427
- Tenidap
activated neutrophil collagenase and, 184
radiographic bone destruction and, 183
- Tetracycline derivatives, mechanisms of
antiangiogenic action by, 266
- Tetracyclines
clinical experience with, 132
effects of, on neutrophil and gingival
collagenases, 112
keratinocytes and, 140
modulation of bone resorption by, 165
non-antimicrobial, 96
 α_1 -protease inhibitor and, 303-304
rheumatoid arthritis and, 194
temporomandibular joint destruction and,
427
- Thioester bond, α_2 M and, 294
- TIMP (tissue inhibitor of metalloproteinase)
activity, his95 important in, 66
- TIMP inhibition, connective tissue
breakdown and, 75
- TIMP mRNA half-life, 54
- TIMP sequences, comparison of, 65
- TIMP-1
fibroblast-type collagenase and, 84
second disulfide knot and, 403
- TIMP-1 and TIMP-2, dental plaque and, 127
- TIMP-1 mutants, more extensive set of, 65
- TIMP-2
human melanoma cell adhesion and
motility and, 233
injured rat artery and, 384
progelatinase A and, 389
regulation of MMP-2 activation and, 57
- TIMPS
characterization of, in plasma, 251
integrity of ECM and, 225
 α_2 -macroglobulin and, 294
metastasis and, 13
MMPs and, 31
resorption of bone matrix and, 168
transferrin degradation inhibited by, 357
- Tissue breakdown, role of TIMP and MMP
inhibition in preventing, 75
- Tissue destruction, periodontal, oral
spirochetes in, 125
- Tissue healing, 433
- Tissue inhibitor of metalloproteinase
(see TIMP)
- Tissue kallikrein, 466
- Tissue remodeling
MMP-TIMP balance in, 226
TIMPs and, 70
- Titanocene dichloride, inhibition of
angiogenesis by, 280, 287
- Transcription
proteins transactivating, 335
retinoids suppressing, 336
- Transfections, cell, mouse 92-kDa type IV
collagenase gene and, 369
- Transferrin, stromelysin enzyme activity and,
356
- Transforming growth factor- β
MMP expression and, 45
repression of rat stromelysin by, 47
- Transforming growth factor- β 1, regulation of
MMP expression by, 51
- Transgenic mice, mouse 92-kDa type IV
collagenase gene and, 369
- Transin, arthritis and, 183
- Treatment, 128
- Triple helix, recognition site in, 22
- Trypsin, treatment with, 297
- Tumor cell invasion, role of MMP-9 in, 325
- Tumor growth, solid, angiogenesis and, 263
- Tumor markers, expansion of concept of, 248
- Tumor necrosis factor- α , stimulation of
production of MPs by, 3
- Tumor progression
causal role of MMPs in, 223
MMPs and, 217
- Tumor suppressor, TIMP-1 behaving as, 67

U rinary HyPro, testing effect of MMP inhibitors with, 184

Urinary pyridinoline, inhibition of, by doxycycline, 416, 419

Uterine MMPs, cefotetan and, 495

V iscosity, 398

Vitamin A analogues, 335

W estern blotting, molecular forms of collagenases characterized by, 115

Wheat sprout complex, 379

X -ray structure, 400

Z ymogen, fibroblast-type collagenase and, 84

Index of Contributors

Abramson, S. R., 362-364

Ahrens, D., 484-485

Aigner, S., 479-481

Ainamo, A., 476-478

Aletras, A., 280-293

Allan, J. A., 365-366

Allen, S. D., 315-323

Altman, R. D., 392-394

Andoh, N., 112-131

Andreassi, S., 493-494

Andriopoulou, P., 280-293

Atkinson, S., 31-41

Baker, T. S., 248-262

Baragi, V. M., 348-350

Baranowski, Z., 379

Barletta, J. P., 315-323

Berkowitz, R., 479-481

Berman, J., 351-355

Bickett, D. M., 351-355

Billedeau, R., 489-492

Binner, S., 294-302

Birkedal-Hansen, B., 84-95, 403-407

Birkedal-Hansen, H., 84-95, 403-407

Bläser, J., 400-402

Bodden, M. K., 84-95, 403-407

Bode, W., 400-402

Bonassar, L. J., 439-443

Borregaard, N., 476-478, 486-488

Brandt, K. D., 199-205, 274, 275, 436-438

Breedveld, F. C., 422-423

Brem, H., 263-272, 276

Brinkerhoff, C. E., 335-347

Brott, D. A., 348-350

Brown, P. D., 217-221, 276

Bueno, J., 456-458

Butler, T. A., 444-446

Caldwell, C. G., 439-443

Cassabonne, M. E., 315-323

Castelhano, A., 489-492

Castellot, J. J., 315-323

Caterina, N. C. M., 84-95, 403-407

Cawston, T., 75-83

Chlebek, K., 414-415

Chubinskaya, S., 414-415

Ciancio, S. G., 132-139

Cleasby, A., 375-378

Clowes, A. W., 384-388, 462-465

Cochran, F. R., 356-358

Cole, A. A., 414-415

Conquer, J. A., 447-449

Conroy, M. C., 348-350

Cosmi, E. V., 493-494

Costello, P. C., 450-452

Crabbe, T., 31-41

Crimmin, M. J., 411-413

Cruz, T. F., 447-449

Cui, T.-Y., 315-323

Curry, V., 75-83

Curto, C., 495-496

Daufeldt, S., 482-483

De Clerck, Y. A., 222-232, 384-388

Dean, D. D., 392-394

Del Maestro, R. F., 450-452

Denhardt, D. T., 65-74

Desrivieres, S., 466-468

Dijkmans, B. A. C., 422-423

DiMartino, M. J., 411-413

Ding, Y., 112-131, 453-455

Docherty, A. J. P., 31-41, 248-262, 275-276,
365-366

Donn, B., 379

Doughty, J., 416-418

Ellis, A., 75-83

Engler, J. A., 84-95

Evans, R. T., 96-111

Feng, R., 489-492

Fernandez, L. A., 315-323

Firth, J. D., 140-151

Fisher, S., 315-323

Flannery, C. R., 380-383

Foellmer, H. G., 315-323

Foidart, J.-M., 369-371

Forough, R., 384-388

Frank, E. H., 439-443

French, D. L., 324-334, 469-471

Fricke, C., 400-402

Fridman, R., 466-468

Fujimoto, N., 359-361, 389-391

Galardy, R. E., 315-323

Galazka, G., 84-95

Galloway, W. A., 411-413

Ganu, V., 416-418

Giese, C., 315-323

Gilbert, J. H., 315-323

Goldberg, R., 416-418

Golden, H., 484-485

Goli, U. B., 22-30

Golub, L. M., 96-111, 140-151, 165-180, 278,
279, 303-314, 419-421, 424-426,
427-430, 431-432, 433-435

Gordon, R. E., 479-481

Goren, A., 427-430

- Gray, R. D., 206-216
 Green, M. D., 351-355
 Greenwald, R. A., *i-ii*, 181-198, 273-279,
 273-274, 275, 276-277, 278, 279,
 419-421, 427-430
 Grima, D. T., 447-449
 Grobelny, D., 315-323
 Grodzinsky, A. J., 439-443

- H**agmann, W. K., 439-443
 Hall, J. E., 303-314
 Haralabopoulos, G., 280-293
 Harber, G. J., 403-407
 Hasenstab, D., 384-388
 Hassell, A. M., 375-378
 Hasty, K. A., 436-438
 Hausknecht, V., 479-481
 Hayakawa, T., 359-361, 389-391
 High, W., 411-413
 Holleran, W. M., 315-323
 Hosokawa, N., 359-361
 Howell, D. S., 392-394
 Huhtala, P., 369-371

- I**ngman, T., 112-131, 453-455, 459-461
 Itoh, Y., 294-302
 Iwata, K., 359-361, 389-391

- J**effries, K. A., 439-443
 Jordan, S. R., 375-378

- K**albhen, D. A., 482-483
 Karimbux, N. Y., 433-435
 Kenagy, R. D., 462-465
 Kjeldsen, L., 476-478, 486-488
 Kleine, T., 400-402
 Kloppenburg, M., 422-423
 Knäuper, V., 367-368
 Kontinen, Y. T., 112-131, 424-426, 431-432,
 453-455, 459-461, 476-478, 486-488
 Kontusaari, S., 369-371
 Krane, S. M., 1-10, 273, 274, 278, 279
 Krikun, G., 479-481

- L**ähdevirta, J., 424-426, 431-432, 476-478
 Lalwani, N. D., 348-350
 Lambert, M. H., 375-378
 Langley, K. E., 222-232, 384-388
 Lapierre, F., 315-323
 Lark, M. W., 439-443, 275
 Lauhio, A., 112-131, 424-426, 431-432,
 476-478
 Lee, H. M., 96-111, 303-314
 Legrand, Y., 466-468
 Leppä, S., 453-455
 Liede, K., 453-455

- Lockwood, C. J., 479-481
 Lopez, H., 315-323
 Lopresti-Morrow, L., 395-397
 Lovejoy, B., 375-378
 Lu, H., 466-468
 Luchene, L. L., 414-415
 Luther, M. A., 375-378
 Lysik, R. M., 248-262

- M**aasjoshusmann, U., 400-402
 Maiti, S. N., 456-458
 Mallée, C., 422-423
 Mallya, S. K., 303-314
 Maragoudakis, M. E., 280-293
 Mase, C., 484-485
 Matrisian, L. M., 42-50
 McCulloch, C. A. G., 152-164, 278, 279
 McGeehan, G. M., 351-355, 375-378
 McNamara, T. F., 96-111
 Menashi, S., 466-468
 Michaelis, J., 459-461
 Missirlis, E., 280-293
 Mitchell, P. G., 395-397
 Moak, S. A., 419-421, 427-430
 Moll, U., 248-262
 Moore, V. L., 439-443
 Morishima, H., 408-410
 Munaut, C., 369-371, 472-475
 Murphy, G., 31-41, 365-366, 367-368

- N**agase, H., 294-302
 Naito, K., 408-410
 Netzel-Arnett, S., 22-30
 Niedbala, M. J., 484-485
 Nip, L., 140-151
 Nishimura, I., 433-435
 Nishimura, S., 408-410
 Nordström, D., 431-432
 Nuovo, G. J., 324-334

- O**'Connell, J., 31-41
 Ohtani, H., 112-131
 Okada, Y., 359-361
 Okuyama, A., 408-410
 Orth, M. W., 414-415
 O'Shea, M., 31-41
 Overall, C. M., 51-64

- P**aguio, C. G., 439-443
 Palao-Marco, F. L., 456-458
 Pan, L., 335-347
 Papp, C., 479-481
 Paterson, C. A., 206-216
 Peristeris, P., 280-293
 Plumpton, T., 75-83
 Pourmotabbed, T., 372-374

Powell, L., 75-83
Pulyaeva, H., 456-458

Qiu, L., 348-350

Rajan, S., 65-74
Ramamurthy, N. S., 96-111, 165-180,
427-430, 433-435, 486-488
Ramos-DeSimone, N., 324-334, 469-471
Ranta, H., 476-478
Ray, J. M., 233-247
Reinemer, P., 400-402
Reiter, L. A., 395-397
Reponen, P., 369-371, 472-475
Rifkin, B. R., 165-180, 427-430, 486-488
Roemer, E. J., 303-314
Rogachefsky, R. A., 392-394
Roth, J. T., 351-355
Rozinski, K., 324-334

Sahlberg, C., 472-475
Salari, A., 22-30
Salo, T., 112-131, 424-426, 431-432,
476-478, 486-488
Sandy, J. D., 380-383
Sapolsky, A. I., 398-399
Sbracia, M., 495-496
Scarpellini, F., 493-494, 495-496
Scarpellini, L., 493-494, 495-496
Schaefer, M. E., 315-323
Schatz, F., 479-481
Schmid, T. M., 414-415
Schnierer, S., 400-402
Schultz, G. S., 315-323
Scuibba, J., 427-430
Sepper, R., 453-455
Sheff, M. F., 398-399
Sherman, D. B., 356-358
Shimada, H., 222-232
Sileski, M., 379
Simon, S. R., 303-314
Sipos, E. P., 263-272
Smith, G. N., Jr., 436-438
Sommerhoff, C. P., 486-488
Soria, C., 466-468
Sorsa, T., 112-131, 279, 424-426, 431-432,
453-455, 459-461, 476-478, 486-488
Spirito, S., 416-418
Stack, R., 315-323
Stein-Picarella, M., 484-485
Steinmeyer, J., 482-483

Stetler-Stevenson, W. G., 233-247, 248-262,
276, 450-452
Suda, H., 408-410
Sullivan, M., 315-323
Summers, B., 315-323
Sweeney, F. J., 395-397

Takeha, S., 112-131
Tamargo, R. J., 263-272
Tanaka, N., 408-410
Taylor, S. M., 222-232
Teronen, O., 112-131, 486-488
Terwiel, J. Ph., 422-423
Thesleff, I., 472-475
Thompson, E. W., 456-458
Tickle, S. P., 248-262
Tigari, R. H., 456-458
Toth-Pal, E., 479-481
Tressler, R., 315-323
Tryggvason, K., 369-371, 472-475
Tschesche, H., 367-368, 400-402, 424-426,
431-432
Turner, G., 427-430
Turoczy, L., 379
Tyrrell, D., 315-323

Uitto, V.-J., 140-151

Van Wart, H. E., 22-30
Vernillo, A. T., 165-180, 486-488

Wagner, C., 351-355
Walther, S. E., 65-74
Ward, R., 31-41, 389-391
Wee, J., 315-323
Weigl, D., 375-378
Weingart, J. D., 263-272
Willenbrock, F., 31-41
Windsor, L. J., 84-95, 403-407
Woessner, J. F., Jr., 11-21, 362-364, 424-426,
444-446

Yermovsky, A., 84-95
Yocum, S. A., 395-397
Yu, M., 456-458
Yuan, Z., 489-492

Zarrabi, H. M., 248-262
Zempo, N., 384-388
Zucker, S., 248-262, 275, 277